RNA Diagnostics Inc. appoints President & CEO

 In News

Rna Diagnostics Inc. appoints President and CEO

Rna Diagnostics Inc. appoints
Dr. Jeremy Bridge-Cook President and CEO

Dr. Jeremy Bridge-Cook

Dr. Ken Pritzker, on behalf of the Board of Directors of Rna Diagnostics Inc., is pleased to announce the appointment of Dr. Jeremy Bridge-Cook to the position of President and Chief Executive Officer of Rna Diagnostics Inc. Dr. Bridge-Cook is a highly accomplished In Vitro Diagnostics (IVD) executive with  comprehensive experience developing and launching innovative IVD products onto global markets. Prior to assuming the President and CEO role at Rna Diagnostics, Dr. Bridge-Cook was engaged for 16 years in progressively senior business development, research and development and general management roles at Tm Bioscience (TMB) and Luminex Corporation, which acquired TMB in 2007. Dr. Bridge-Cook was a corporate officer and Senior Vice President of R&D at Luminex, a NASDAQ listed corporation that develops, manufacturers and markets IVD and biological testing technologies for the clinical diagnostic and life science industries. Dr. Bridge-Cook was instrumental in delivering new molecular diagnostic systems and assays from inception to successful commercial launch. Dr. Bridge-Cook obtained a B.Sc., Biology from McMaster University and a Ph.D., Immunology from University of Toronto.

“Jeremy brings an exceptional combination of business, scientific skills and IVD industry experience to his role as President and CEO of Rna Diagnostics. His extensive IVD industry experience is directly pertinent to the commercialization of the RNA Disruption Assay™ (RDA™) technology and the objective of delivering RDA services to cancer centres around the world” says Dr. Ken Pritzker.

Dr. Pritzker, Co-Founder and current President and CEO of Rna Diagnostics, will continue to be part of the executive leadership team. He will assume the role of Chief Innovation Officer and will continue as a member of the Board of Directors of Rna Diagnostics.

“I am excited about assuming the role of President and CEO of Rna Diagnostics and leading the commercialization of the RNA Disruption Assay™ (RDA™). RDA™ has tremendous potential to become a standard of care in chemotherapy management and to help improve the lives of cancer patients worldwide,“ says Dr. Bridge-Cook.

About Rna Diagnostics Inc.
Rna Diagnostics is a cancer diagnostics company providing a platform of prognostic biomarker tools to help improve the lives of cancer patients treated with chemotherapy. Founded in 2010, Rna Diagnostics’ first product is  The RNA Disruption Assay™ (RDA™) providing physicians with an evaluation of how individual patients are responding to chemotherapy as early as 14 days after 1st cycle of treatment. If chemotherapy is working, the physician and patient can continue treatment with confidence. If chemotherapy is not working, physicians may consider alternate therapies. For patients, this means avoiding harmful side effects and the possibility for improved survival outcomes. www.rnadiagnostics.com. ​

Copyright © 2016 Rna Diagnostics Inc., All rights reserved.


Leave a Comment

Contact Us

If you’re interested in learning more about angel investing, please contact us.

Not readable? Change text. captcha txt